Merck Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in China
Reduces animal testing through molecular-based technology
Merck announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. Utilizing Merck’s Blazar® Rodent Panel, Biotheus’ turn-around-time (TAT) of its cell line characterization reduced from around 60 days to 14 days.
Symbolic image
Unsplash
“The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space,” said Marc Jaffré, Managing Director, Life Science business sector, Merck China. “Merck has a 75-year history of biosafety testing experience. With this state-of-the-art platform, Merck’s Blazar® Rodent Panel can support our biopharmaceutical clients in China to accelerate their scientific breakthroughs and produce safe, life-saving therapies faster.”
“The Blazar® Rodent Panel from Merck is one of the few technologies available on the market that will empower us in expediting approvals for IND and BLA in China and beyond,” said Xu Yingda, Vice President of Chemical Manufacturing and Control, Biotheus Inc. “We look forward to our continued collaboration with Merck, a global leader in biosafety testing and regulatory services, in the development of novel drugs to treat cancer and inflammatory disease, and expand our clinical trial activities worldwide.”
The award-winning Blazar® Rodent Panel from Merck can detect a much broader range of adventitious viruses compared to traditional Polymerase Chain Reaction methods as it targets conserved regions within virus families. The Blazar® Rodent Panel allows the biopharma industry to move away from using traditional animal experiments to detect rodent origin virus in the cell banks used in the production of the biologics. Introduced in 2020, it also reduces the use of animals in accordance with the 4Rs principles – replacement, reduction, refinement and responsibility.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Novel vaccine against a range of diseases caused by the Epstein-Barr virus - Start-up “EBViously“ announces first details of its EBV vaccine candidate
Rechargeable nanotorch - Afterglow luminescence imaging tracks cell-based microrobots in real time
New potential way to control spread of insect-borne disease - Cross-disciplinary team launches public conversation about new way to manage ecosystems
List_of_subjects_in_Gray's_Anatomy:_Alphabetical:_Y
Charting the anatomy of three molecular channels
Archives_of_Pediatrics_&_Adolescent_Medicine
Category:Norwegian_Red_Cross
BASF’s Nutrition & Health division to focus on growth and increased competitiveness - Reduction of about 260 positions worldwide by end of 2015
